Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice
Atezolizumab, a programmed-death ligand-1 (PD-L1) inhibitor, is a novel treatment option for patients with metastatic urothelial cancer (mUC). Clinical prognostic factors, survival outcomes, and the safety of patients with mUC treated with atezolizumab, in a real-world setting, were investigated.
Guardado en:
Autores principales: | Mencinger Marina, Mangaroski Dusan, Bokal Urska |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Sciendo
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e129ffa1f0f8468498cf304d0108d71e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
por: Utpal Kumar, et al.
Publicado: (2021) -
The use of atezolizumab in combination with chemotherapy in first-line of metastatic small cell lung cancer. Case report
por: Nikolai A. Ognerubov, et al.
Publicado: (2021) -
A review on the evolution of immunotherapy in bladder carcinoma
por: Milena Gulinac, et al.
Publicado: (2020) -
Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence
por: Sara Elena Rebuzzi, et al.
Publicado: (2021) -
New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
por: Seetharamu N, et al.
Publicado: (2017)